688393.SH
安必平
SSE · Healthcare · Medical - Instruments & Supplies · CN
CNY 19.58
−3.36%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 351.5M | 344.4M | 470.8M | 497.3M | 507.4M |
| Cost of Revenue | 123.7M | 125.2M | 154.3M | 156.7M | 146.8M |
| Gross Profit | 227.8M | 219.2M | 316.5M | 340.6M | 360.6M |
| Operating Expenses | |||||
| R&D Expense | 33.0M | 36.1M | 45.5M | 62.7M | 67.4M |
| SG&A Expense | — | — | — | — | — |
| General & Admin Expense | 72.8M | 76.6M | 71.3M | 77.1M | 75.8M |
| Selling & Marketing Expense | 164.0M | 164.9M | 192.5M | 182.7M | 186.0M |
| Other Expenses | — | — | — | — | — |
| Total Operating Expenses | 272.3M | 277.9M | 305.6M | 319.3M | 327.0M |
| Cost and Expenses | 396.0M | 403.2M | 459.8M | 476.0M | 473.7M |
| Operating Income (EBIT) | (40.0M) | (51.4M) | 11.0M | 21.5M | 28.7M |
| Non-Operating | |||||
| Interest Income | — | — | — | — | — |
| Interest Expense | — | — | — | — | — |
| Net Interest Income | — | — | — | — | — |
| Other Non-Op Income/Expense | — | — | — | — | — |
| Non-Operating Income (excl Interest) | — | — | — | — | — |
| EBT (Pre-Tax Income) | (43.8M) | (55.2M) | 9.4M | 16.8M | 28.8M |
| Income Tax Expense | (3.5M) | (4.4M) | (5.5M) | (4.2M) | (539.2K) |
| Bottom Line | |||||
| Net Income | (37.8M) | (47.0M) | 21.3M | 40.1M | 42.7M |
| Earnings from Cont. Ops | (40.7M) | (50.8M) | 14.9M | 21.0M | 29.3M |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (37.8M) | (47.0M) | 21.3M | 40.1M | 42.7M |
| Per Share | |||||
| Basic EPS | (CN¥0.40) | (CN¥0.50) | CN¥0.23 | CN¥0.43 | CN¥0.46 |
| Diluted EPS | (CN¥0.40) | (CN¥0.50) | CN¥0.23 | CN¥0.42 | CN¥0.45 |
| Revenue Per Share | CN¥3.83 | CN¥3.66 | CN¥5.09 | CN¥5.34 | CN¥5.47 |
| Shares | |||||
| Basic Shares Outstanding | 91.7M | 94.0M | 92.6M | 93.2M | 92.8M |
| Diluted Shares Outstanding | 91.7M | 94.0M | 92.6M | 93.2M | 92.8M |
| Profitability Metrics | |||||
| EBITDA | — | (1.4M) | 56.0M | 65.7M | 65.0M |
| D&A | — | 50.1M | 45.0M | 44.2M | 36.3M |
| EBIT | — | — | — | — | — |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Mar 1, 2026